Evaluation of the Frequency of Osteopontin Gene Polymorphism (rs28357094 T>G) and its Receptor Gene (ITGA4- rs1449263 A>G) in Multiple Sclerosis Patients in Comparison to Healthy Controls in Isfahan, Iran, Population

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Immunology, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Cellular and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Professor, Department of Neurosciences, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 PhD Student, Department of Cellular and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). Various factors including genetic and environmental factors are involved in the prevalence of MS. The Osteopontin (OPN) and its receptor Integrins alpha-4/beta-1 (ITGA4) have important role in immune response, so their encoding gene could be considered as a candidate for susceptibility to MS diseases. In the present study, we evaluated the frequency of OPN (rs28357094T > G) and ITGA4 (rs1449263A>G) polymorphisms in MS patients compared with healthy controls in Isfahan, Iran population.Methods: Blood samples were collected from 100 patients with multiple sclerosis and 100 healthy controls. After DNA extraction, OPN (rs28357094) and ITGA4(rs1449263) polymorphisms were detected with high resolution melt real time polymerase chain reaction (HRM Real Time PCR) technique. The results were analyzed with the SPSS software.Findings: In this study, frequency of TT genotype (OPN-rs28357094) (P = 0.020, OR = 1.85) and AA genotype (ITGA4 - rs1449263) (P = 0.012, OR = 2.10) in Patients with multiple sclerosis were higher than the control group significantly.Conclusion: The results of this study show that rs28357094 T>G on OPN gene and ITGA4-rs1449263A > G polymorphisms were associated with susceptibility to multiple sclerosis in Isfahan population.

Keywords

References

  1. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol 2012; 142(1): 2-8.
  2. Pandit L, Ban M, Sawcer S, Singhal B, Nair S, Radhakrishnan K, et al. Evaluation of the established non-MHC multiple sclerosis loci in an Indian population. Mult Scler 2011; 17(2): 139-43.
  3. Etemadifar M, Maghzi AH. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Mult Scler 2011; 17(8): 1022-7.
  4. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010; 9(7): 727-39.
  5. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004; 3(2): 104-10.
  6. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008; 19(5-6): 333-45.
  7. Poggi A, Zocchi MR. NK cell autoreactivity and autoimmune diseases. Front Immunol 2014; 5: 27.
  8. Glas J, Seiderer J, Bayrle C, Wetzke M, Fries C, Tillack C, et al. The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease. PLoS One 2011; 6(12): e29309.
  9. Shimizu Y, Ota K, Ikeguchi R, Kubo S, Kabasawa C, Uchiyama S. Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica. J Neuroimmunol 2013; 263(1-2): 148-51.
  10. Kaleta B. Role of osteopontin in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz ) 2014; 62(6): 475-82.
  11. Zhang F, Luo W, Li Y, Gao S, Lei G. Role of osteopontin in rheumatoid arthritis. Rheumatol Int 2015; 35(4): 589-95.
  12. Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008; 181(11): 7480-8.
  13. O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 2000; 68(4): 495-502.
  14. Bornsen L, Khademi M, Olsson T, Sorensen PS, Sellebjerg F. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 2011; 17(1): 32-42.
  15. Salvi V, Scutera S, Rossi S, Zucca M, Alessandria M, Greco D, et al. Dual regulation of osteopontin production by TLR stimulation in dendritic cells. J Leukoc Biol 2013; 94(1): 147-58.
  16. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007; 8(1): 74-83.
  17. Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 2009; 9(6): 440-7.
  18. Chiocchetti A, Orilieri E, Cappellano G, Barizzone N, D' Alfonso S, D' Annunzio G, et al. The osteopontin gene +1239A/C single nucleotide polymorphism is associated with type 1 diabetes mellitus in the Italian population. Int J Immunopathol Pharmacol 2010; 23(1): 263-9.
  19. Barizzone N, Marchini M, Cappiello F, Chiocchetti A, Orilieri E, Ferrante D, et al. Association of osteopontin regulatory polymorphisms with systemic sclerosis. Hum Immunol 2011; 72(10): 930-4.
  20. D'Alfonso S, Barizzone N, Giordano M, Chiocchetti A, Magnani C, Castelli L, et al. Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2005; 52(2): 539-47.
  21. Chiocchetti A, Indelicato M, Bensi T, Mesturini R, Giordano M, Sametti S, et al. High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood 2004; 103(4): 1376-82.
  22. Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G, et al. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 2004; 20(1): 87-96.
  23. O'Doherty C, Roos IM, Antiguedad A, Aransay AM, Hillert J, Vandenbroeck K. ITGA4 polymorphisms and susceptibility to multiple sclerosis. J Neuroimmunol 2007; 189(1-2): 151-7.
  24. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003; 8(3): 223-46.
  25. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009; 9(6): 393-407.
  26. Nagai S, Hashimoto S, Yamashita T, Toyoda N, Satoh T, Suzuki T, et al. Comprehensive gene expression profile of human activated T(h)1- and T(h)2-polarized cells. Int Immunol 2001; 13(3): 367-76.
  27. Marciano R, D'Annunzio G, Minuto N, Pasquali L, Santamaria A, Di DM, et al. Association of alleles at polymorphic sites in the Osteopontin encoding gene in young type 1 diabetic patients. Clin Immunol 2009; 131(1): 84-91.
  28. Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB. Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun 2009; 10(5): 487-94.
  29. Hummelshoj T, Ryder LP, Madsen HO, Odum N, Svejgaard A. A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression. Mol Immunol 2006; 43(7): 980-6.
Journal of Isfahan Medical School
Volume 34, Issue 380 - Serial Number 380
March and April 2016
Pages 422-429

Files

History

  • Receive Date: 26 October 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics